BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from its Chairman, Richard Staelin, PhD, highlighting sales growth, cost control, and strategic advancements. The company reported a small profit for calendar year 2025, attributed to disciplined cost control measures including office relocation and staff reductions. These efforts, combined with targeted advertising campaigns and expanded social media outreach, have led to an increase in monthly sales across both OTC and professional markets.
The company has launched advertising campaigns aimed at medical professionals, including surgeons, pain specialists, and chiropractors, to increase awareness of its RecoveryRx device as a non-opioid pain management option. Additionally, consumer-focused social media campaigns targeting Generation X are intended to boost brand visibility for chronic musculoskeletal pain relief.
BioElectronics is also pursuing a clinical trial partner for RecoveryRx in ambulatory surgical centers and orthopedic practices, with the goal of qualifying for reimbursement under the federal NO PAIN Act initiative. This could support broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, the company continues arbitration proceedings in Singapore and China against a former distributor for breach of contract, emphasizing its commitment to protecting intellectual property and shareholder interests.
A key strategic milestone is the advancement of the distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, and Electrome has placed its initial purchase order. Manufacturing is underway, and Electrome plans a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This partnership provides another avenue to increase consumer access to FDA-cleared, drug-free pain therapy products.
Chairman Staelin expressed optimism about the growing interest in non-drug pain management solutions and the company's position in the electroceutical and non-opioid pain management markets. He noted that while challenges remain for emerging medical technology companies, BioElectronics is focused on sustainable growth through clinical market development, professional outreach, consumer education, and international opportunities.
For more information, visit the company's website at https://www.bielcorp.com/.
